MarketPR
The agreement governing Boundless Bio's (BOLD) planned acquisition of Serapha Bio, Inc. was revised on August 28, 2026, when the parties executed Amendment No.
1 to the June 22 Agreement and Plan of Merger and Reorganization. Boulder Merger Sub Corp., a wholly owned Boundless Bio subsidiary, will merge into Serapha, leaving Serapha as the surviving entity under BOLD's umbrella.
The next confirmable milestone is the Company Pre-Closing Financing, which the amendment references but does not size. The mechanics the amendment adds Three changes carry operational weight.
Serapha restricted stock unit awards, vested and unvested alike, will convert at closing into Boundless Bio RSU awards rather than settle for cash; the share count on each award adjusts by the Exchange Ratio specified in the original agreement.
Keep reading